Kromek (AIM: KMK) wins $1.4m medical imaging order, but repeat sales are the real prize

Kromek Group plc (AIM: KMK), a United Kingdom-based developer of radiation detection technology for medical imaging and chemical, biological, radiological and nuclear applications, has received a follow-on order worth US$1.4 million from an existing original equipment manufacturer customer in its Advanced Imaging division. Announced on 5 November 2026, the order covers cadmium zinc telluride detector components used in the customer’s medical systems, with deliveries beginning immediately and expected to be completed over the following 12 months. The agreement provides evidence of repeat demand for Kromek’s imaging technology and adds visibility to revenues spanning the current and subsequent financial years. However, the company’s recent results show that substantial licensing income continues to influence reported profitability, making the growth of ordinary detector sales central to assessing the sustainability of its business model.

What does Kromek’s US$1.4 million medical imaging order cover?

The order is for cadmium zinc telluride, or CZT, detector components that an existing equipment manufacturer will incorporate into medical imaging systems. Kromek has not disclosed the customer’s identity, the number of components being supplied or the individual unit price. It has confirmed that delivery is expected over approximately 12 months, creating a defined period for fulfilling the order.

The order is commercially different from a new research collaboration or a preliminary technology assessment. It involves the supply of detector components to a customer that already has an established relationship with Kromek, suggesting that the technology has progressed beyond initial evaluation for at least the application covered by the order.

Repeat purchasing can be particularly valuable for component suppliers because manufacturers often undertake substantial design, testing and qualification work before incorporating a specialist component into a finished system. Once a technology has been integrated into an equipment architecture, further orders may follow as the customer’s manufacturing programme continues.

That does not guarantee a particular order frequency or volume. Original equipment manufacturers can change production schedules, alter equipment designs or adjust component purchasing in response to demand. However, a repeat order provides more direct evidence of continuing commercial activity than a statement about the size of the medical imaging market.

Kromek has not disclosed the contract’s gross margin, payment terms or whether the customer has committed to additional purchases beyond the new order. Its immediate financial contribution will therefore depend on delivery timing, manufacturing costs and the accounting treatment applied as performance obligations are satisfied.

Why are CZT detectors becoming important in medical imaging?

CZT is a semiconductor material used in radiation detection applications. Its properties allow detector systems to convert incoming radiation into electrical signals, supporting imaging technologies that require precise measurement of radiation energy and position. Kromek develops CZT detector components for applications including nuclear medicine and advanced computed tomography.

One important market is single photon emission computed tomography, or SPECT, which is used in nuclear medicine to examine how radiopharmaceuticals are distributed within the body. CZT detector technology can support systems designed to improve imaging performance and measurement capabilities. The commercial importance depends on how medical equipment manufacturers integrate these components into products and whether hospitals adopt the resulting systems.

Kromek is also developing technology for photon-counting computed tomography, which represents a different approach to measuring X-ray photons from that used in conventional CT detector systems. The technology is attracting industry interest because of its potential to support improved imaging information and certain diagnostic applications.

The November order confirms demand for CZT-based components but does not identify the customer’s specific medical system or establish that the order relates to photon-counting CT. It would therefore be inappropriate to classify the contract as a particular scanner programme without additional disclosure.

The commercial opportunity extends across multiple medical imaging applications, but actual revenue growth will depend on product qualification, manufacturing scale, customer adoption and long-term supply arrangements.

How does the new order fit Kromek’s financial performance?

Kromek reported revenue of £27.1 million for the financial year ended 30 April 2026, compared with £26.5 million in FY2025. Advanced Imaging contributed £19.9 million, slightly below the previous year’s £20.3 million. The headline figures therefore show modest overall growth and a small decline in the reported imaging segment, despite stronger activity in underlying commercial products.

The company reported that Advanced Imaging revenue increased 76% to £6.7 million on an underlying basis after excluding income associated with its Siemens Healthineers enablement agreement and a separate non-recurring major sale. The comparable underlying figure was £3.8 million in FY2025. This adjusted comparison is useful because it isolates a smaller revenue base associated more closely with continuing commercial activity.

Group revenue excluding the relevant licensing contribution and non-recurring sale increased 39% to approximately £13.9 million from £10.0 million. That improvement suggests stronger demand across Kromek’s ordinary products and development activities, even though the total reported revenue increase was only around 2%.

The distinction is particularly relevant when evaluating the November order. A US$1.4 million follow-on purchase contributes to the category of commercial activity Kromek needs to expand if detector manufacturing is to become a larger source of revenue. Its significance lies not simply in the absolute contract value, but in whether similar orders become more frequent and larger over time.

Kromek’s ability to increase recurring component supply would reduce the proportion of its financial performance dependent on occasional large licensing arrangements or exceptional transactions. The company’s results show progress in that direction, but the underlying revenue base remains relatively small.

Why did Kromek’s gross margin fall despite stronger underlying demand?

Kromek reported gross margin of 62.8% in FY2026, down from 80.9% in FY2025. The decline reflects a change in revenue composition, particularly the lower contribution from high-margin licensing income associated with the Siemens Healthineers agreement. It should not automatically be interpreted as deterioration in the profitability of the company’s ordinary detector products.

The company’s revenue included approximately £10.0 million of licensing income in FY2026, compared with £16.5 million in the previous year. Product revenue increased from approximately £7.0 million to £13.8 million, while research and development revenue rose from £3.0 million to £3.3 million.

These figures illustrate a substantial shift towards product sales. Licensing revenue represented approximately 37% of total FY2026 revenue, down from 62% a year earlier, while products represented 51%, compared with 27% previously. The change makes reported gross margin less dependent on the unusually favourable economics of intellectual-property licensing.

Management expects gross margin to return towards the mid-50% range in FY2027 as the revenue mix evolves further. That forecast implies that the group may record lower headline gross margins even while product volumes grow. The economic outcome will depend on whether higher sales and manufacturing efficiency generate more absolute profit and cash.

Kromek also reported adjusted EBITDA of £8.1 million, down from £10.3 million, and pre-tax profit of £2.5 million, compared with £3.1 million a year earlier. These movements demonstrate that the transition towards greater product revenue has not yet generated enough additional earnings to replace the declining contribution from high-margin licensing.

The next stage of the strategy therefore requires volume growth that improves absolute profitability, rather than relying on the maintenance of historical percentage margins.

What role does the Siemens Healthineers agreement play in Kromek’s outlook?

Kromek entered into an enablement and patent licensing arrangement with Siemens Medical Solutions USA, Inc., part of Siemens Healthineers, during FY2025. Under the enablement agreement, Kromek is due to receive US$37.5 million in cash across four instalments over the relevant contractual period. The arrangement supports the development and manufacture of CZT detector technology for medical imaging applications.

The company reported that it had received US$32.5 million under the agreement by the time of its September 2026 results announcement. The remaining US$5 million payment is associated with completion of delivery, which management expected during the financial year ending 30 April 2029. Revenue recognition under the agreement follows the satisfaction of accounting performance obligations rather than the timing of individual cash payments alone.

The Siemens relationship provides evidence of the value assigned to Kromek’s technology and intellectual property by a major medical equipment company. However, the licensing arrangement is financially different from the repeat sale of detector components. Licensing revenue can be concentrated around contractual milestones or recognised over defined periods, while manufacturing revenue depends on continuing customer demand and product delivery.

Kromek also expects initial supply revenues under its Siemens Healthineers arrangement during FY2027. Separately, it is progressing deliveries to Spectrum Dynamics as that customer expands the commercial rollout of SPECT equipment. These are named existing relationships with their own contractual arrangements and should not be assumed to be the unidentified customer behind the November US$1.4 million order.

The combination of licensing, technical collaboration and commercial component sales gives Kromek several potential revenue sources. A more mature financial model would involve a greater proportion of earnings generated through continuing product demand rather than a small number of significant licensing transactions.

Can Kromek manufacture detectors profitably at greater scale?

Scaling specialist detector production involves more than obtaining customer orders. Manufacturing performance depends on material quality, production yields, component consistency, testing requirements and the ability to meet customers’ delivery schedules. For medical imaging equipment, reliability and repeatability are particularly important because components form part of sophisticated systems operating under demanding technical specifications.

Kromek has been investing in process automation and manufacturing improvements, including work at its United States CZT facility. Management has identified productivity and yield improvement as priorities for increasing output without proportionately increasing production costs. Successful automation could allow the company to supply larger order volumes while protecting the economics of each component.

The company also maintains a substantial intellectual-property portfolio, reporting more than 190 patents and patent applications at the end of FY2026. This provides a technological foundation for its products, but the financial value of the portfolio depends on adoption, licensing and profitable manufacturing.

Customer concentration remains relevant. Kromek’s FY2026 financial statements reported approximately £14.1 million of revenue from its largest commercial customer within Advanced Imaging. That represented more than half of total group revenue, although the figure includes activities with different revenue characteristics and should not be treated as a measure of dependence on the unidentified November order customer.

Large established customers can provide substantial revenue visibility, but changes in their product strategies or procurement schedules can have an outsized effect on a comparatively small supplier. Expanding the number of customers generating repeat orders would improve the diversity of commercial revenue.

Is Kromek’s balance sheet strong enough to support commercial growth?

Kromek ended April 2026 with approximately £4.2 million of cash and cash equivalents, compared with £1.7 million a year earlier. Net debt excluding lease liabilities was approximately £1.5 million, compared with net cash of £1.2 million in FY2025. The company also secured a £6 million three-year revolving credit facility during the financial year.

The movement towards net debt reflected investment in working capital and the timing of customer payments. Management reported that approximately £1 million of expected receipts arrived shortly after the financial year end, which would have reduced the reported net debt figure had they been received earlier. Nevertheless, growing manufacturing activity can increase working-capital requirements even when revenue and profit are improving.

Specialist component production requires spending on materials, work in progress, equipment and technical staff before customer payments are necessarily received. The ability to manage payment terms and manufacturing inventory therefore becomes increasingly important as the Advanced Imaging division expands.

Kromek’s chemical, biological, radiological and nuclear detection division provides an additional source of revenue and diversification. It reported revenue growth of 17% to approximately £7.3 million during FY2026, supported by government and security-related business. The company expects further activity from existing framework arrangements and its international distribution network.

The combination of medical imaging and security-related technology offers exposure to different end markets, but both require continued investment and disciplined commercial execution. Growth across the divisions would be more valuable if it produces positive cash flow without requiring a corresponding increase in borrowing.

What does the latest Kromek share-price movement reveal?

Kromek shares were quoted around 5.5 pence to 5.7 pence in a 5 November market snapshot, with the indicated price movement positive by approximately 3%. The stock remained within a wider 52-week range of roughly 5.2 pence to 13 pence, illustrating the scale of the valuation decline from earlier trading levels.

The company’s equity value was approximately £37 million at the available market reference. At this scale, relatively modest changes in expectations concerning orders, cash generation or profitability may have a material effect on investor sentiment. The market response to the November announcement should therefore be viewed in the context of the company’s broader revenue mix and funding position rather than as a direct valuation of the new contract.

Kromek has reported positive pre-tax profit in recent years, but its earnings have been materially influenced by licensing income. The investment question is whether the improving underlying product business can eventually support profitability and cash generation as those contributions become less dominant.

The US$1.4 million order strengthens evidence of repeat customer demand and supports revenue visibility into the next financial year. The more significant confirmation would be a sustained increase in ordinary detector sales accompanied by improved manufacturing efficiency and a larger customer base.

Can Kromek convert specialist technology into a sustainable product business?

Kromek enters FY2027 with commercial relationships across medical imaging and security detection, a growing underlying product business and established technology licensing arrangements. Management expects significant revenue growth across both major divisions while forecasting gross margins closer to levels normally associated with its product mix.

Delivering that growth will require the company to fulfil existing contracts, increase output for equipment manufacturers and manage the working-capital implications of a larger production operation. New orders will be valuable, but repeat purchasing from a wider group of customers would provide stronger evidence of commercial durability.

The November order demonstrates that an existing medical imaging customer is continuing to procure Kromek’s detector components. The next measurable test is whether that pattern develops across multiple customers and produces enough gross profit and cash to compensate for the declining relative contribution of high-margin licensing revenue.

Kromek’s progress towards a sustainable manufacturing-led business will become clearer through its FY2027 revenue mix, product sales growth, operating profitability and cash-flow performance. Those financial measures will determine whether the value of its specialised technology is increasingly reflected in recurring commercial earnings.

What should Kromek Group (KMK) shareholders know about the US$1.4m imaging order?

• Kromek has secured a US$1.4 million follow-on order from an existing medical imaging equipment manufacturer.
• The contract covers CZT-based detector components, with deliveries expected over approximately 12 months.
• The customer has not been identified and future order commitments have not been disclosed.
• FY2026 revenue increased to £27.1 million from £26.5 million.
• Advanced Imaging underlying revenue increased 76% to £6.7 million on the company’s adjusted definition.
• Product revenue increased substantially, while the contribution from high-margin licensing declined.
• Gross margin fell to 62.8% from 80.9%, reflecting the changing revenue mix.
• Kromek reported £4.2 million in cash and £1.5 million of net debt excluding leases at its April 2026 year end.
• Siemens Healthineers and Spectrum Dynamics remain important existing commercial relationships.
• Repeat orders, manufacturing efficiency and positive cash conversion will determine the sustainability of future growth.